Skip to main content
Top
Published in: Experimental Hematology & Oncology 1/2015

Open Access 01-12-2015 | Review

Paraneoplastic neurological complications of breast cancer

Authors: Ibrahim Fanous, Patrick Dillon

Published in: Experimental Hematology & Oncology | Issue 1/2015

Login to get access

Abstract

Breast cancer is the most frequent cause of cancer of women in much of the world. In countries with screening programs, breast cancer is often detected before clinical symptoms are apparent, but occasionally the occurrence of a paraneoplastic syndrome precedes the identification of cancer. In breast cancer, there are known to be paraneoplastic endocrine syndromes and neurologic syndromes. The neurologic syndromes are often hard to identify and treat. The neurologic syndromes associated with breast cancer include cerebellar degeneration, sensorimotor neuropathy, retinopathy, stiff-persons syndrome, encephalitis, and opsoclonus–myoclonus. Most of these are mediated by antibodies against known neural antigens, although some cases appear to be mediated by non-humoral mechanisms. Treatments differ depending upon the syndrome type and etiology. Outcomes also vary depending upon duration of disease, the treatments used and the responsiveness of the underlying cancer. A thorough review of the published literature is provided along with recommendations for management and future research.
Literature
2.
go back to reference DeSantis CE, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42.PubMedCrossRef DeSantis CE, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42.PubMedCrossRef
3.
go back to reference Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81(9):1109–12.PubMedCrossRef Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81(9):1109–12.PubMedCrossRef
4.
5.
go back to reference Said S, et al. Paraneoplastic limbic encephalitis, an uncommon presentation of a common cancer: case report and discussion. Am J Case Rep. 2013;14:391–4.PubMedPubMedCentralCrossRef Said S, et al. Paraneoplastic limbic encephalitis, an uncommon presentation of a common cancer: case report and discussion. Am J Case Rep. 2013;14:391–4.PubMedPubMedCentralCrossRef
6.
7.
go back to reference Gultekin SH, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.PubMedCrossRef Gultekin SH, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.PubMedCrossRef
9.
go back to reference Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 2008;7(4):1388–94.PubMedCrossRef Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 2008;7(4):1388–94.PubMedCrossRef
11.
go back to reference Fernandez Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005;230(2):187–98.PubMedCrossRef Fernandez Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005;230(2):187–98.PubMedCrossRef
12.
go back to reference Tan HT, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276(23):6880–904.PubMedCrossRef Tan HT, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276(23):6880–904.PubMedCrossRef
13.
go back to reference Domschke C, et al. Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. Cancer Immunol Immunother. 2011;60(3):401–11.PubMedCrossRef Domschke C, et al. Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. Cancer Immunol Immunother. 2011;60(3):401–11.PubMedCrossRef
14.
go back to reference Sommerfeldt N, et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 2006;66(16):8258–65.PubMedCrossRef Sommerfeldt N, et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 2006;66(16):8258–65.PubMedCrossRef
15.
go back to reference Pradat PF, et al. Pure cerebellar syndrome associated with anti-Hu antibodies. Rev Neurol (Paris). 1995;151(5):341–3. Pradat PF, et al. Pure cerebellar syndrome associated with anti-Hu antibodies. Rev Neurol (Paris). 1995;151(5):341–3.
16.
go back to reference Peterson K, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7.PubMedCrossRef Peterson K, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7.PubMedCrossRef
17.
go back to reference Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA. 1996;93(10):4529–36.PubMedPubMedCentralCrossRef Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA. 1996;93(10):4529–36.PubMedPubMedCentralCrossRef
18.
go back to reference Waterhouse DM, Natale RB, Cody RL. Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991;68(8):1835–41.PubMedCrossRef Waterhouse DM, Natale RB, Cody RL. Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991;68(8):1835–41.PubMedCrossRef
19.
go back to reference Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol. 1988;24(4):559–67.PubMedCrossRef Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol. 1988;24(4):559–67.PubMedCrossRef
20.
go back to reference Furneaux HM, et al. Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1989;86(8):2873–7.PubMedPubMedCentralCrossRef Furneaux HM, et al. Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1989;86(8):2873–7.PubMedPubMedCentralCrossRef
21.
go back to reference Dropcho EJ, et al. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1987;84(13):4552–6.PubMedPubMedCentralCrossRef Dropcho EJ, et al. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1987;84(13):4552–6.PubMedPubMedCentralCrossRef
22.
go back to reference Donfrancesco R, et al. Anti-Yo antibodies in children with ADHD: first results about serum cytokines. J Atten Disord, 2016. Donfrancesco R, et al. Anti-Yo antibodies in children with ADHD: first results about serum cytokines. J Atten Disord, 2016.
23.
go back to reference Lennon VA. Anti-Purkinje cell cytoplasmic and neuronal nuclear antibodies aid diagnosis of paraneoplastic autoimmune neurological disorders. J Neurol Neurosurg Psychiatry. 1989;52(12):1438–9.PubMedPubMedCentralCrossRef Lennon VA. Anti-Purkinje cell cytoplasmic and neuronal nuclear antibodies aid diagnosis of paraneoplastic autoimmune neurological disorders. J Neurol Neurosurg Psychiatry. 1989;52(12):1438–9.PubMedPubMedCentralCrossRef
24.
go back to reference Rojas-Marcos I, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore). 2003;82(3):216–23. Rojas-Marcos I, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore). 2003;82(3):216–23.
25.
go back to reference Adamus G, et al. Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy. J Ophthalmic Inflamm Infect. 2011;1(3):111–21.PubMedPubMedCentralCrossRef Adamus G, et al. Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy. J Ophthalmic Inflamm Infect. 2011;1(3):111–21.PubMedPubMedCentralCrossRef
26.
27.
go back to reference Cho NC, et al. Selective loss of S-cones in diabetic retinopathy. Arch Ophthalmol. 2000;118(10):1393–400.PubMedCrossRef Cho NC, et al. Selective loss of S-cones in diabetic retinopathy. Arch Ophthalmol. 2000;118(10):1393–400.PubMedCrossRef
28.
go back to reference Sittler T, et al. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008;14(12):3896–905.PubMedCrossRef Sittler T, et al. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008;14(12):3896–905.PubMedCrossRef
29.
go back to reference Weleber RG, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005;139(5):780–94.PubMedCrossRef Weleber RG, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005;139(5):780–94.PubMedCrossRef
30.
go back to reference Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun. 2009;32(2):133–9.PubMedPubMedCentralCrossRef Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun. 2009;32(2):133–9.PubMedPubMedCentralCrossRef
32.
go back to reference Misiuk-Hojło M, et al. Cancer-associated retinopathy in patients with breast carcinoma. Arch Immunol Ther Exp (Warsz). 2007;55(4):261–5.CrossRef Misiuk-Hojło M, et al. Cancer-associated retinopathy in patients with breast carcinoma. Arch Immunol Ther Exp (Warsz). 2007;55(4):261–5.CrossRef
33.
go back to reference Weizman DA, Leong WL. Anti-Ri antibody opsoclonus–myoclonus syndrome and breast cancer: a case report and a review of the literature. J Surg Oncol. 2004;87(3):143–5.PubMedCrossRef Weizman DA, Leong WL. Anti-Ri antibody opsoclonus–myoclonus syndrome and breast cancer: a case report and a review of the literature. J Surg Oncol. 2004;87(3):143–5.PubMedCrossRef
34.
go back to reference Bataller L, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain. 2001;124(Pt 2):437–43.PubMedCrossRef Bataller L, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain. 2001;124(Pt 2):437–43.PubMedCrossRef
35.
go back to reference Gatti G, et al. Paraneoplastic neurological disorders in breast cancer. Breast. 2003;12(3):203–7.PubMedCrossRef Gatti G, et al. Paraneoplastic neurological disorders in breast cancer. Breast. 2003;12(3):203–7.PubMedCrossRef
36.
go back to reference Hanaoka T, et al. A case of occult breast cancer with paraneoplastic polyneuropathy. Breast Cancer. 1997;4(3):187–91.PubMedCrossRef Hanaoka T, et al. A case of occult breast cancer with paraneoplastic polyneuropathy. Breast Cancer. 1997;4(3):187–91.PubMedCrossRef
37.
go back to reference Antoine JC. Paraneoplastic peripheral neuropathies. Rev Neurol (Paris). 2008;164(12):1068–72.CrossRef Antoine JC. Paraneoplastic peripheral neuropathies. Rev Neurol (Paris). 2008;164(12):1068–72.CrossRef
39.
go back to reference Sahashi K, et al. Anti-Ma2 antibody related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry. 2003;74(9):1332–5.PubMedPubMedCentralCrossRef Sahashi K, et al. Anti-Ma2 antibody related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry. 2003;74(9):1332–5.PubMedPubMedCentralCrossRef
40.
go back to reference Kawamura N, et al. A patient with paraneoplastic limbic encephalitis induced by breast cancer presenting with hypersomnia. Rinsho Shinkeigaku. 2005;45(8):575–8.PubMed Kawamura N, et al. A patient with paraneoplastic limbic encephalitis induced by breast cancer presenting with hypersomnia. Rinsho Shinkeigaku. 2005;45(8):575–8.PubMed
41.
42.
go back to reference Yamamoto T, Tsuji S. Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis. Brain Nerve. 2010;62(8):838–51.PubMed Yamamoto T, Tsuji S. Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis. Brain Nerve. 2010;62(8):838–51.PubMed
43.
go back to reference Morita A, Kamei S. Limbic encephalitis with antibodies against intracellular antigens. Brain Nerve. 2010;62(4):347–55.PubMed Morita A, Kamei S. Limbic encephalitis with antibodies against intracellular antigens. Brain Nerve. 2010;62(4):347–55.PubMed
45.
46.
go back to reference Dorn C, et al. Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report. Arch Gynecol Obstet. 2003;269(1):62–5.PubMedCrossRef Dorn C, et al. Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report. Arch Gynecol Obstet. 2003;269(1):62–5.PubMedCrossRef
47.
go back to reference Shams’ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(Pt 6):1409–18.PubMedCrossRef Shams’ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(Pt 6):1409–18.PubMedCrossRef
48.
go back to reference Rojas I, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55(5):713–5.PubMedCrossRef Rojas I, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55(5):713–5.PubMedCrossRef
49.
go back to reference Mathew RM, et al. Paraneoplastic cerebellar degeneration: yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci. 2006;250(1–2):153–5.PubMedCrossRef Mathew RM, et al. Paraneoplastic cerebellar degeneration: yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci. 2006;250(1–2):153–5.PubMedCrossRef
50.
go back to reference Keime-Guibert F, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479–82.PubMedPubMedCentralCrossRef Keime-Guibert F, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479–82.PubMedPubMedCentralCrossRef
51.
go back to reference Widdess-Walsh P, et al. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003;63(2):187–90.PubMedCrossRef Widdess-Walsh P, et al. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003;63(2):187–90.PubMedCrossRef
52.
go back to reference Huober J, et al. Paraneoplastic retinopathy in 2 patients with breast carcinoma. Zentralbl Gynakol. 1997;119(6):278–81.PubMed Huober J, et al. Paraneoplastic retinopathy in 2 patients with breast carcinoma. Zentralbl Gynakol. 1997;119(6):278–81.PubMed
53.
go back to reference Thirkill CE, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321(23):1589–94.PubMedCrossRef Thirkill CE, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321(23):1589–94.PubMedCrossRef
54.
55.
go back to reference Sampedro A, et al. Ocular paraneoplastic syndrome: cancer-associated retinopathy. Arch Soc Esp Oftalmol. 2013;88(10):407–9.PubMedCrossRef Sampedro A, et al. Ocular paraneoplastic syndrome: cancer-associated retinopathy. Arch Soc Esp Oftalmol. 2013;88(10):407–9.PubMedCrossRef
56.
go back to reference Maverakis E, et al. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):135–44.PubMedCrossRef Maverakis E, et al. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):135–44.PubMedCrossRef
57.
go back to reference Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132(1–2):72–82.PubMedCrossRef Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132(1–2):72–82.PubMedCrossRef
58.
go back to reference Polans AS, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92(20):9176–80.PubMedPubMedCentralCrossRef Polans AS, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92(20):9176–80.PubMedPubMedCentralCrossRef
60.
go back to reference Rai G, et al. Human retinal S-antigen: t cell epitope mapping in posterior uveitis patients. Exp Mol Pathol. 2001;70(2):140–5.PubMedCrossRef Rai G, et al. Human retinal S-antigen: t cell epitope mapping in posterior uveitis patients. Exp Mol Pathol. 2001;70(2):140–5.PubMedCrossRef
61.
go back to reference Adamus G, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78(2):120–9.PubMedCrossRef Adamus G, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78(2):120–9.PubMedCrossRef
62.
go back to reference Limentani SA, et al. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Res Treat. 2016;156(2):319–30.PubMedCrossRef Limentani SA, et al. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Res Treat. 2016;156(2):319–30.PubMedCrossRef
63.
go back to reference Hu P, Pollard JD, Chan-Ling T. Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity. Am J Pathol. 2000;156(4):1139–49.PubMedPubMedCentralCrossRef Hu P, Pollard JD, Chan-Ling T. Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity. Am J Pathol. 2000;156(4):1139–49.PubMedPubMedCentralCrossRef
64.
go back to reference Adamus G, et al. Significance of anti-retinal autoantibodies in cancer-associated retinopathy with gynecological cancers. J Clin Exp Ophthalmol. 2013;4(6):307.PubMedPubMedCentralCrossRef Adamus G, et al. Significance of anti-retinal autoantibodies in cancer-associated retinopathy with gynecological cancers. J Clin Exp Ophthalmol. 2013;4(6):307.PubMedPubMedCentralCrossRef
65.
66.
go back to reference Pratesi F, et al. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol. 2000;27(1):109–15.PubMed Pratesi F, et al. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol. 2000;27(1):109–15.PubMed
67.
68.
go back to reference Morohoshi K, et al. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun. 2009;33(3–4):247–54.PubMedCrossRef Morohoshi K, et al. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun. 2009;33(3–4):247–54.PubMedCrossRef
69.
go back to reference Cherepanoff S, et al. Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2006;34(6):590–5.PubMedCrossRef Cherepanoff S, et al. Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2006;34(6):590–5.PubMedCrossRef
70.
go back to reference Penfold PL, et al. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1990;228(3):270–4.PubMedCrossRef Penfold PL, et al. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1990;228(3):270–4.PubMedCrossRef
71.
go back to reference Vu TH, Jager MJ, Chen DF. The immunology of glaucoma. Asia Pac J Ophthalmol (Phila). 2012;1(5):303–11.CrossRef Vu TH, Jager MJ, Chen DF. The immunology of glaucoma. Asia Pac J Ophthalmol (Phila). 2012;1(5):303–11.CrossRef
72.
go back to reference Eadie JA, Ip MS, Ver Hoeve JN. Localized retinal manifestations of paraneoplastic autoimmune retinopathy. Retin Cases Brief Rep. 2014;8(4):318–21.PubMedCrossRef Eadie JA, Ip MS, Ver Hoeve JN. Localized retinal manifestations of paraneoplastic autoimmune retinopathy. Retin Cases Brief Rep. 2014;8(4):318–21.PubMedCrossRef
73.
go back to reference Shih NY, et al. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol. 2010;40(7):663–9.PubMedCrossRef Shih NY, et al. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol. 2010;40(7):663–9.PubMedCrossRef
74.
go back to reference He P, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007;98(8):1234–40.PubMedCrossRef He P, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007;98(8):1234–40.PubMedCrossRef
75.
go back to reference Ohguro H, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160–7.PubMed Ohguro H, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci. 1999;40(13):3160–7.PubMed
76.
go back to reference Sawyer RA, et al. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–13.PubMedCrossRef Sawyer RA, et al. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81(5):606–13.PubMedCrossRef
77.
78.
go back to reference Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9(2):275–84.PubMedCrossRef Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9(2):275–84.PubMedCrossRef
79.
80.
go back to reference Sommer C, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365(9468):1406–11.PubMedCrossRef Sommer C, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365(9468):1406–11.PubMedCrossRef
82.
go back to reference Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71(24):1955–8.PubMedPubMedCentralCrossRef Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71(24):1955–8.PubMedPubMedCentralCrossRef
83.
go back to reference Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc. 1989;64(6):629–36.PubMedCrossRef Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc. 1989;64(6):629–36.PubMedCrossRef
84.
go back to reference Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. 1999;131(7):522–30.PubMedCrossRef Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. 1999;131(7):522–30.PubMedCrossRef
85.
go back to reference Nguyen-Huu BK, et al. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord. 2006;21(8):1285–7.PubMedCrossRef Nguyen-Huu BK, et al. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord. 2006;21(8):1285–7.PubMedCrossRef
86.
go back to reference De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178(6):2219–23.PubMedCrossRef De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178(6):2219–23.PubMedCrossRef
87.
go back to reference Folli F, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med. 1993;328(8):546–51.PubMedCrossRef Folli F, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med. 1993;328(8):546–51.PubMedCrossRef
88.
go back to reference Rene R, et al. Stiff man syndrome (Moersch and Woltman syndrome). Description of two cases. Neurologia. 1990;5(8):284–7.PubMed Rene R, et al. Stiff man syndrome (Moersch and Woltman syndrome). Description of two cases. Neurologia. 1990;5(8):284–7.PubMed
89.
go back to reference Agarwal PA, Ichaporia NR. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India. 2010;58(3):449–51.PubMedCrossRef Agarwal PA, Ichaporia NR. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India. 2010;58(3):449–51.PubMedCrossRef
90.
go back to reference Rosin L, et al. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology. 1998;50(1):94–8.PubMedCrossRef Rosin L, et al. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology. 1998;50(1):94–8.PubMedCrossRef
91.
go back to reference Thumen A, Moser A. An uncommon paraneoplastic Ri-positive opsoclonus–myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer. J Neurol. 2010;257(7):1215–7.PubMedCrossRef Thumen A, Moser A. An uncommon paraneoplastic Ri-positive opsoclonus–myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer. J Neurol. 2010;257(7):1215–7.PubMedCrossRef
92.
go back to reference Lemieux J, et al. Paraneoplastic encephalomyelitis, stiff person syndrome and breast carcinoma. Can J Neurol Sci. 2011;38(5):790–2.PubMedCrossRef Lemieux J, et al. Paraneoplastic encephalomyelitis, stiff person syndrome and breast carcinoma. Can J Neurol Sci. 2011;38(5):790–2.PubMedCrossRef
93.
go back to reference Taguchi Y, et al. Case of antiamphiphysin antibody-positive stiff-person syndrome with breast cancer diagnosed by FDG-PET. Rinsho Shinkeigaku. 2008;48(6):410–4.PubMedCrossRef Taguchi Y, et al. Case of antiamphiphysin antibody-positive stiff-person syndrome with breast cancer diagnosed by FDG-PET. Rinsho Shinkeigaku. 2008;48(6):410–4.PubMedCrossRef
94.
go back to reference Petzold GC, et al. Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. Ann Neurol. 2004;55(2):286–90.PubMedCrossRef Petzold GC, et al. Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. Ann Neurol. 2004;55(2):286–90.PubMedCrossRef
95.
go back to reference Lorenzoni PJ, et al. Electrophysiological characteristics in four patients from Brazil with stiff person syndrome. J Clin Neurosci. 2012;19(6):889–91.PubMedCrossRef Lorenzoni PJ, et al. Electrophysiological characteristics in four patients from Brazil with stiff person syndrome. J Clin Neurosci. 2012;19(6):889–91.PubMedCrossRef
96.
go back to reference Schreiber AL, et al. Atypical clinically diagnosed stiff-person syndrome response to dantrolene–a refractory case. Muscle Nerve. 2012;45(3):454–5.PubMedCrossRef Schreiber AL, et al. Atypical clinically diagnosed stiff-person syndrome response to dantrolene–a refractory case. Muscle Nerve. 2012;45(3):454–5.PubMedCrossRef
97.
go back to reference Newton JC, et al. Trialing of intrathecal baclofen therapy for refractory stiff-person syndrome. Reg Anesth Pain Med. 2013;38(3):248–50.PubMedCrossRef Newton JC, et al. Trialing of intrathecal baclofen therapy for refractory stiff-person syndrome. Reg Anesth Pain Med. 2013;38(3):248–50.PubMedCrossRef
98.
go back to reference Harned ME, Salles SS, Grider JS. An introduction to trialing intrathecal baclofen in patients with hemiparetic spasticity: a description of 3 cases. Pain Physician. 2011;14(5):483–9.PubMed Harned ME, Salles SS, Grider JS. An introduction to trialing intrathecal baclofen in patients with hemiparetic spasticity: a description of 3 cases. Pain Physician. 2011;14(5):483–9.PubMed
99.
go back to reference Maramattom BV. Intrathecal baclofen pump implantation in a case of stiff person syndrome. Neurol India. 2010;58(1):115–7.PubMedCrossRef Maramattom BV. Intrathecal baclofen pump implantation in a case of stiff person syndrome. Neurol India. 2010;58(1):115–7.PubMedCrossRef
100.
go back to reference Ughratdar I, Sivakumar G, Basu S. Spinal cord stimulation to abort painful spasms of atypical stiff limb syndrome. Stereotact Funct Neurosurg. 2010;88(3):183–6.PubMedCrossRef Ughratdar I, Sivakumar G, Basu S. Spinal cord stimulation to abort painful spasms of atypical stiff limb syndrome. Stereotact Funct Neurosurg. 2010;88(3):183–6.PubMedCrossRef
101.
go back to reference Vicente-Valor MI, et al. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report. J Clin Pharm Ther. 2013;38(1):71–3.PubMedCrossRef Vicente-Valor MI, et al. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report. J Clin Pharm Ther. 2013;38(1):71–3.PubMedCrossRef
102.
go back to reference Peterson K, Forsyth PA, Posner JB. Paraneoplastic sensorimotor neuropathy associated with breast cancer. J Neurooncol. 1994;21(2):159–70.PubMedCrossRef Peterson K, Forsyth PA, Posner JB. Paraneoplastic sensorimotor neuropathy associated with breast cancer. J Neurooncol. 1994;21(2):159–70.PubMedCrossRef
103.
go back to reference Sadot E, et al. Breast cancer and motor neuron disease: clinical study of seven cases. Amyotroph Lateral Scler. 2007;8(5):288–91.PubMedCrossRef Sadot E, et al. Breast cancer and motor neuron disease: clinical study of seven cases. Amyotroph Lateral Scler. 2007;8(5):288–91.PubMedCrossRef
104.
105.
go back to reference Minisini AM, et al. Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat. 2007;105(2):133–8.PubMedCrossRef Minisini AM, et al. Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat. 2007;105(2):133–8.PubMedCrossRef
106.
go back to reference Camdessanche JP, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125(Pt 1):166–75.PubMedCrossRef Camdessanche JP, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125(Pt 1):166–75.PubMedCrossRef
107.
go back to reference Wabbels BK, et al. Bilateral tonic pupils with evidence of anti-hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica. 2004;218(2):141–3.PubMedCrossRef Wabbels BK, et al. Bilateral tonic pupils with evidence of anti-hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica. 2004;218(2):141–3.PubMedCrossRef
108.
go back to reference Scheid R, et al. A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry. 2004;75(2):338–40.PubMedPubMedCentral Scheid R, et al. A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry. 2004;75(2):338–40.PubMedPubMedCentral
109.
go back to reference Sculier JP, et al. Neurologic disorders in patients with small cell lung cancer. Cancer. 1987;60(9):2275–83.PubMedCrossRef Sculier JP, et al. Neurologic disorders in patients with small cell lung cancer. Cancer. 1987;60(9):2275–83.PubMedCrossRef
111.
go back to reference Lawn ND, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78(11):1363–8.PubMedCrossRef Lawn ND, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78(11):1363–8.PubMedCrossRef
112.
go back to reference Dalmau J, et al. Anti-Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59–72.CrossRef Dalmau J, et al. Anti-Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59–72.CrossRef
113.
go back to reference Candler P, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2004;75(10):1411–5.PubMedPubMedCentralCrossRef Candler P, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2004;75(10):1411–5.PubMedPubMedCentralCrossRef
114.
go back to reference Uchuya M, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60(4):388–92.PubMedPubMedCentralCrossRef Uchuya M, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60(4):388–92.PubMedPubMedCentralCrossRef
115.
go back to reference Vedeler CA, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682–90.PubMedCrossRef Vedeler CA, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682–90.PubMedCrossRef
116.
go back to reference Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19.PubMedCrossRef Titulaer MJ, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19.PubMedCrossRef
117.
go back to reference Greenlee JE. Treatment of paraneoplastic neurologic disorders. Curr Treat Options Neurol. 2010;12(3):212–30.PubMedCrossRef Greenlee JE. Treatment of paraneoplastic neurologic disorders. Curr Treat Options Neurol. 2010;12(3):212–30.PubMedCrossRef
118.
go back to reference Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus–myoclonus. Neurology. 1993;43(1):207–11.PubMedCrossRef Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus–myoclonus. Neurology. 1993;43(1):207–11.PubMedCrossRef
119.
go back to reference Smith JH, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus–myoclonus: treatment response to plasmapheresis. Arch Neurol. 2011;68(8):1069–72.PubMedCrossRef Smith JH, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus–myoclonus: treatment response to plasmapheresis. Arch Neurol. 2011;68(8):1069–72.PubMedCrossRef
120.
go back to reference Ross AT, Zeman W. Opsoclonus, occult carcinoma, and chemical pathology in dentate nuclei. Arch Neurol. 1967;17(5):546–51.PubMedCrossRef Ross AT, Zeman W. Opsoclonus, occult carcinoma, and chemical pathology in dentate nuclei. Arch Neurol. 1967;17(5):546–51.PubMedCrossRef
121.
go back to reference Cogan DG. Opsoclonus, body tremulousness, and benign encephalitis. Arch Ophthalmol. 1968;79(5):545–51.PubMedCrossRef Cogan DG. Opsoclonus, body tremulousness, and benign encephalitis. Arch Ophthalmol. 1968;79(5):545–51.PubMedCrossRef
122.
go back to reference Dassan P, Clarke C, Sharp DJ. A case of poststreptococcal opsoclonus–myoclonus syndrome. Mov Disord. 2007;22(10):1490–1.PubMedCrossRef Dassan P, Clarke C, Sharp DJ. A case of poststreptococcal opsoclonus–myoclonus syndrome. Mov Disord. 2007;22(10):1490–1.PubMedCrossRef
123.
go back to reference Ikawa M, Kuriyama M. Paraneoplastic retinopathy and optic neuropathy. Brain Nerve. 2010;62(4):371–6.PubMed Ikawa M, Kuriyama M. Paraneoplastic retinopathy and optic neuropathy. Brain Nerve. 2010;62(4):371–6.PubMed
Metadata
Title
Paraneoplastic neurological complications of breast cancer
Authors
Ibrahim Fanous
Patrick Dillon
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2015
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-016-0058-x

Other articles of this Issue 1/2015

Experimental Hematology & Oncology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine